Neogen Chemicals Recommends Final Dividend of ₹1/Share for FY26; Reports Q4 Results
Neogen Chemicals recommended a final dividend of ₹1 per share for FY26, subject to shareholder approval. The company announced its audited financial results for Q4 FY26 and the full year. Revised project timelines and costs were also provided for its subsidiary, Neogen Ionics Limited.
The dividend recommendation is a positive development. The financial results are stable, and the revised project timelines for the subsidiary are noted.
The recommendation of a final dividend and the approval of audited financial results generally have a positive impact on investor sentiment.
Neogen Chemicals Limited announced the outcome of its Board Meeting held on May 16, 2026. The Board approved the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2026, with an unmodified audit opinion from M/s. Chandabhoy & Jassoobhoy, Chartered Accountants.
The company recommended a final dividend of ₹1 per Equity Share for the Financial Year 2025-26, subject to shareholder approval at the upcoming 37th Annual General Meeting (AGM). The record date for the dividend and the AGM date will be intimated in due course.
Additionally, the Board approved amendments to "the Code for prevention of insider trading in the securities of Neogen Chemicals Limited". The company also provided updates on its wholly-owned subsidiary, Neogen Ionics Limited, including revised projected costs and timelines for the Dahej and Pakhajan projects. The Dahej Phase 1 project is now expected to cost ₹428 crore with a revised timeline of Feb 2027, and the Pakhajan Phase 2 project is projected at ₹1,367 crore with a timeline of Mar 2027, totaling ₹1,795 crore.
The financial results show a Profit for the period (Net Profit) of ₹14.66 crore for the quarter ended March 31, 2026, compared to ₹5.19 crore in the same quarter last year. For the full financial year ended March 31, 2026, the Net Profit was ₹46.96 crore, compared to ₹48.41 crore in the previous year. The company also reported key financial ratios and updated information on its debt instruments and credit ratings.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.